Are There Therapeutic Benefits of Cannabinoid Products in Adult Mental Illness?

Tibbo, Philip G; McKee, Kyle A; Meyer, Jeffrey H; Crocker, Candice E; Aitchison, Katherine J; Lam, Raymond W; Crockford, David N

Tibbo, Philip G; McKee, Kyle A; Meyer, Jeffrey H; Crocker, Candice E; Aitchison, Katherine J; Lam, Raymond W; Crockford, David N.

Afiliación

Tibbo PG; Department of Psychiatry, 3688Dalhousie University, Halifax, Nova Scotia, Canada.
McKee KA; Department of Psychiatry, 3688Dalhousie University, Halifax, Nova Scotia, Canada.
Meyer JH; Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
Crocker CE; Department of Psychiatry, 3688Dalhousie University, Halifax, Nova Scotia, Canada; Department of Diagnostic Imaging, Nova Scotia Health Authority, Halifax, Nova Scotia, Canada.
Aitchison KJ; Departments of Psychiatry and Medical Genetics, University of Alberta, Edmonton, Alberta, Canada; Neuroscience and Mental Health Institute, University of Alberta, Edmonton, Alberta, Canada; Mood and Anxiety Disorders Program, University of Alberta Hospital, Edmonton, Alberta, Canada.
Lam RW; Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada.
Crockford DN; Department of Psychiatry, University of Calgary, Alberta, Canada.

Can J Psychiatry ; 66(2): 185-194, 2021 02.

Article en En | MEDLINE | ID: mdl-32911977

Asunto(s)

Cannabinoides; Trastornos Mentales; Psiquiatría; Adulto; Canadá; Humanos; Trastornos Mentales/tratamiento farmacológico; Sociedades Médicas

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Psiquiatría / Cannabinoides / Trastornos Mentales Tipo de estudio: Diagnostic_studies País/Región como asunto: America do norte Idioma: En Revista: Can J Psychiatry Año: 2021 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google